Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0IP9V
|
||||
| Former ID |
DNC008508
|
||||
| Drug Name |
PH-709829
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H17N3O2
|
||||
| Canonical SMILES |
C1CN2CC1CC(C2)NC(=O)C3=NC=C4C(=C3)C=CO4
|
||||
| InChI |
1S/C15H17N3O2/c19-15(13-6-11-2-4-20-14(11)7-16-13)17-12-5-10-1-3-18(8-10)9-12/h2,4,6-7,10,12H,1,3,5,8-9H2,(H,17,19)/t10-,12-/m1/s1
|
||||
| InChIKey |
PTGWFYYEAUFEAS-ZYHUDNBSSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine receptor 3A | Target Info | Inhibitor | [1] | |
| Neuronal acetylcholine receptor protein, alpha-7 chain | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Serotonergic synapsehsa04020:Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Cholinergic synapse | |||||
| Nicotine addiction | |||||
| Chemical carcinogenesis | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | 5HT3 type receptor mediated signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway | ||||
| Nicotinic acetylcholine receptor signaling pathway | |||||
| Reactome | Ligand-gated ion channel transportR-HSA-629594:Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | ||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Iron uptake and transportWP706:SIDS Susceptibility Pathways | |||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2008 Jun 15;18(12):3611-5. Epub 2008 May 1.Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.